Rallybio Corp (RLYB) Stock Price & Analysis

Rallybio Corp (RLYB) rose 0.00% to USD 16.31 as of July 25, 2026 at 03:51 UTC, according to Nexqual real-time market data.

RLYB last closed at USD 16.31; the session ranged USD 16–16.58 on volume of 41,589 shares. Market capitalization is —, with a 52-week range of USD 3.2–17.57 (NCM). Source: Nexqual, July 25, 2026 at 03:51 UTC.

Key Statistics (as of July 25, 2026 at 03:51 UTC)

Technical Analysis (RLYB)

Nexqual's technical model rates RLYB "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:51 UTC.

From Rallybio Corp's Latest SEC 10-K Filing (filed 2026-03-16)

Key Strengths & Strategy (as disclosed to the SEC)

• We utilize a multi-layered approach that includes acquiring intellectual property rights through purchase or exclusive license, filing and prosecuting U.S. and foreign patent applications directed to our own innovations, and developing and protecting proprietary know-how to maintain our competitive position.
• Government Regulation of Drug and Biological Products In the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act, (the "FDCA"), and in the case of biologics, also under the Public Health Service Act (the "PHSA"), and their implementing regulations.
• Potential benefits of our approach We believe PTR represents an attractive development opportunity for RLYB116 for several reasons.
• However, direct oral anticoagulants are generally less effective in preventing recurrent thromboembolic events, most notably strokes. 4 T a b le of Contents Potential benefits of our approach We believe APS is an attractive indication to pursue as part of a comprehensive development strategy for two reasons.

Partnerships

• Concurrently with the execution and delivery of the Merger Agreement, certain investors entered into subscription agreements with Candid, pursuant to which such investors have agreed to purchase, immediately prior to the Merger, shares of Candid common stock representing an aggregate commitment of approximately $505.5 million in the concurrent financing (the "Concurrent Financing").
• Our Strategy In 2025, the Company made a decision to evaluate strategic alternatives, with a goal of enhancing long term shareholder value that culminated with the signing of the Merger Agreement with Candid, a clinical-stage biotechnology company advancing a leading portfolio of TCE therapeutics for autoimmune diseases on March 1, 2026.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:51 UTC. This page is informational and not investment advice.